Literature DB >> 15906167

The talinolol double-peak phenomenon is likely caused by presystemic processing after uptake from gut lumen.

Werner Weitschies1, Annika Bernsdorf, Thomas Giessmann, Michael Zschiesche, Christiane Modess, Vera Hartmann, Claudia Mrazek, Danilo Wegner, Stefan Nagel, Werner Siegmund.   

Abstract

PURPOSE: Evaluation of the double-peak phenomenon during absorption of the beta(1)-selective blocker talinolol relative to paracetamol, which is well absorbed from all parts of the gut, and relative to vitamin A, which is absorbed via the lymphatic pathway.
METHODS: Talinolol was given with paracetamol and retinyl palmitate in fast-disintegrating, enteric-coated, and rectal soft capsules to 8 fasting male healthy subjects (21-29 years, 68-86 kg). To evaluate whether the talinolol double-peak is associated with processes of food absorption, a breakfast was served 1 h after administration of a fast disintegrating capsule.
RESULTS: Bioavailability of talinolol in enteric-coated and rectal capsules was significantly reduced by about 50% and 80%, respectively, despite unchanged bioavailability of paracetamol. Double-peaks appeared after 2-3 h and 4-6 h with talinolol given as fast-liberating capsules. Food increased the maximum concentrations significantly (223 +/- 76 microg/ml vs. 315 +/- 122 microg/ml, p < 0.05) and shifted the second peak of talinolol to shorter t(max) values (3.8 +/- 1.2 h vs. 2.1 +/- 0.6 h, p < 0.05), which was associated with faster absorption of retinyl palmitate. Pharmacokinetic model fits showed that about half of the oral talinolol dose given with and without meal is drained from the intestine via a presystemic storage compartment.
CONCLUSIONS: The double-peak phenomenon of talinolol is likely caused by a presystemic storage compartment, which represents the complex interplay of heterogeneous uptake and kick-back transport processes along the intestinal-hepatic absorption pathway.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15906167     DOI: 10.1007/s11095-005-2588-5

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  52 in total

Review 1.  Enterohepatic circulation: physiological, pharmacokinetic and clinical implications.

Authors:  Michael S Roberts; Beatrice M Magnusson; Frank J Burczynski; Michael Weiss
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 2.  Pharmacokinetic strategies in deciphering atypical drug absorption profiles.

Authors:  Honghui Zhou
Journal:  J Clin Pharmacol       Date:  2003-03       Impact factor: 3.126

3.  Unexpected effect of verapamil on oral bioavailability of the beta-blocker talinolol in humans.

Authors:  U I Schwarz; T Gramatté; J Krappweis; A Berndt; R Oertel; O von Richter; W Kirch
Journal:  Clin Pharmacol Ther       Date:  1999-03       Impact factor: 6.875

Review 4.  Transport and metabolism of vitamin A.

Authors:  R Blomhoff
Journal:  Nutr Rev       Date:  1994-02       Impact factor: 7.110

5.  Intestinal drug absorption during induced net water absorption in man; a mechanistic study using antipyrine, atenolol and enalaprilat.

Authors:  H Lennernäs; O Ahrenstedt; A L Ungell
Journal:  Br J Clin Pharmacol       Date:  1994-06       Impact factor: 4.335

6.  Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells.

Authors:  V D Makhey; A Guo; D A Norris; P Hu; J Yan; P J Sinko
Journal:  Pharm Res       Date:  1998-08       Impact factor: 4.200

7.  Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans.

Authors:  Thomas Giessmann; Karen May; Christiane Modess; Danilo Wegner; Ute Hecker; Michael Zschiesche; Peter Dazert; Markus Grube; Eike Schroeder; Rolf Warzok; Ingolf Cascorbi; Heyo K Kroemer; Werner Siegmund
Journal:  Clin Pharmacol Ther       Date:  2004-09       Impact factor: 6.875

8.  Paracetamol absorption from different sites in the human small intestine.

Authors:  T Gramatté; K Richter
Journal:  Br J Clin Pharmacol       Date:  1994-06       Impact factor: 4.335

9.  P-glycoprotein increases from proximal to distal regions of human small intestine.

Authors:  Stéphane Mouly; Mary F Paine
Journal:  Pharm Res       Date:  2003-10       Impact factor: 4.200

Review 10.  The complexities of hepatic drug transport: current knowledge and emerging concepts.

Authors:  Priyamvada Chandra; Kim L R Brouwer
Journal:  Pharm Res       Date:  2004-05       Impact factor: 4.580

View more
  12 in total

Review 1.  Mass spectrometry-based targeted proteomics as a tool to elucidate the expression and function of intestinal drug transporters.

Authors:  Stefan Oswald; Christian Gröer; Marek Drozdzik; Werner Siegmund
Journal:  AAPS J       Date:  2013-08-28       Impact factor: 4.009

2.  Effect of dose escalation on the in vivo oral absorption and disposition of glycylsarcosine in wild-type and Pept1 knockout mice.

Authors:  Dilara Jappar; Yongjun Hu; David E Smith
Journal:  Drug Metab Dispos       Date:  2011-08-31       Impact factor: 3.922

3.  Blonanserin's interesting food-effect observations: is lymphatic transport involved?

Authors:  Nuggehally R Srinivas
Journal:  Eur J Clin Pharmacol       Date:  2011-04-06       Impact factor: 2.953

4.  C (max) and t (max) verification using Fibonacci sequence and absorption rate.

Authors:  Tomasz Grabowski; Jerzy J Jaroszewski; Beata Borucka; Hubert Ziółkowski
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2012-07-14       Impact factor: 2.441

5.  Analysis of Complex Absorption After Multiple Dosing: Application to the Interaction Between the P-glycoprotein Substrate Talinolol and Rifampicin.

Authors:  Michael Weiss; David Z D'Argenio; Werner Siegmund
Journal:  Pharm Res       Date:  2022-09-26       Impact factor: 4.580

6.  Improved oral bioavailability of BCS class 2 compounds by self nano-emulsifying drug delivery systems (SNEDDS): the underlying mechanisms for amiodarone and talinolol.

Authors:  Anna Elgart; Irina Cherniakov; Yanir Aldouby; Abraham J Domb; Amnon Hoffman
Journal:  Pharm Res       Date:  2013-05-18       Impact factor: 4.200

7.  Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms.

Authors:  Annika Bernsdorf; Thomas Giessmann; Christiane Modess; Danilo Wegner; Stefanie Igelbrink; Ute Hecker; Sierk Haenisch; Ingolf Cascorbi; Bernd Terhaag; Werner Siegmund
Journal:  Br J Clin Pharmacol       Date:  2006-04       Impact factor: 4.335

8.  Concentration-dependent effect of naringin on intestinal absorption of beta(1)-adrenoceptor antagonist talinolol mediated by p-glycoprotein and organic anion transporting polypeptide (Oatp).

Authors:  Yoshiyuki Shirasaka; Yan Li; Yuta Shibue; Erika Kuraoka; Hildegard Spahn-Langguth; Yukio Kato; Peter Langguth; Ikumi Tamai
Journal:  Pharm Res       Date:  2008-11-12       Impact factor: 4.200

9.  Unexpected effect of concomitantly administered curcumin on the pharmacokinetics of talinolol in healthy Chinese volunteers.

Authors:  He Juan; Bernd Terhaag; Zang Cong; Zhang Bi-Kui; Zhu Rong-Hua; Wang Feng; Su Fen-Li; Song Juan; Tang Jing; Peng Wen-Xing
Journal:  Eur J Clin Pharmacol       Date:  2007-04-28       Impact factor: 3.064

10.  Sex-, feeding-, and circadian time-dependency of P-glycoprotein expression and activity - implications for mechanistic pharmacokinetics modeling.

Authors:  Alper Okyar; Swati A Kumar; Elisabeth Filipski; Enza Piccolo; Narin Ozturk; Helena Xandri-Monje; Zeliha Pala; Kristin Abraham; Ana Rita Gato de Jesus Gomes; Mehmet N Orman; Xiao-Mei Li; Robert Dallmann; Francis Lévi; Annabelle Ballesta
Journal:  Sci Rep       Date:  2019-07-19       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.